Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Yun-Han Lin

1PUBLICATIONS
23CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

Sort by Publication Date:
|Apr 28, 2025
PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis.

Sheue-Fen Tzeng, Yi-Ru Yu, Jaeoh Park

Pageof 1

Frequent Collaborators

1 joint publications

Sheue-Fen Tzeng

1 joint publications

Yi-Ru Yu

1 joint publications

Jaeoh Park

1 joint publications

Janusz von Renesse

1 joint publications

Huey-Wen Hsiao

1 joint publications

Chen-Hsuan Hsu

1 joint publications

Josep Garnica

1 joint publications

Jintian Chen

1 joint publications

Lu-Ting Chiu

1 joint publications

Jonas Santol

Frequent Collaborators

1 joint publications

Sheue-Fen Tzeng

1 joint publications

Yi-Ru Yu

1 joint publications

Jaeoh Park

1 joint publications

Janusz von Renesse

Top Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on : Jul 12, 2018

8.5K
See more related videos

Top Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on : Jul 12, 2018

8.5K
See more related videos